Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Protocol ID
J1S-MC-JV02
Disease (Sub Disease)
Synovial Sarcoma
Diagnosis Stage
Relapsed/refractory
Location
VIC
Sponsor
Eli Lilly and Company
Trial Status
Open
Sites
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Months to 29 Years
International registry ID's
NCT04145700
Back to Registry
Study Title Randomized Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed Recurrent or Refractory Synovial Sarcoma
Protocol ID J1S-MC-JV02
Disease (Sub Disease) Synovial Sarcoma
Diagnosis Stage Relapsed/refractory
Location VIC
Sponsor Eli Lilly and Company
Links https://clinicaltrials.gov/ct2/show/NCT04145700
Trial Status Open
Trial Open Date 02/08/2021
Sites Royal Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility 12 Months to 29 Years
International registry ID's NCT04145700